HomeHome
ProductsProducts
Building BlocksBuilding Blocks
Heterocyclic ScaffoldsHeterocyclic Scaffolds
PurinesPurines
BemnifosbuvirBemnifosbuvir

Bemnifosbuvir

CAS No.	1998705-64-8
MDL No.	N/A
MF	C₂₄H₃₃FN₇O₇P
MW	581.50
InChI Key	OISLSHLAXHALQZ-LZEIJKKFSA-N

CUSTOM SYNTHESIS

Pricing & Availability

Pack Size	Purity	Price	Availability	Action
-	-	On Request	On Request
Custom synthesis and bulk supply options are available upon request.

Product Information

CAS No.	1998705-64-8
Product Name	Bemnifosbuvir

Heavy Atom Count	40	Rotatable Bond Count	11
Atom Stereo Count	6	Bond Stereo Count	0
HBA	13	HBD	4
TPSA	184.970 Å²	Charge	0
Exact Mass	581.21631	Complexity	1390.66
pKa	7.130	XLogP	2.570

Studies related to this compound and its mechanism of action

AT-527, a Double Prodrug of a Guanosine Nucleotide Analog, Is a Potent Inhibitor of SARS-CoV-2 and a Promising Oral Antiviral for Treatment of COVID-19.

Antimicrobial agents and chemotherapy • Vol. 65, Issue 4 • 2021

PMID: 33558299 PMC: PMC8097421 DOI: 10.1128/AAC.02479-20

Preclinical evaluation of AT-527, a novel guanosine nucleotide prodrug with potent, pan-genotypic activity against hepatitis C virus.

PloS one • Vol. 15, Issue 1 • 2020

PMID: 31914458 PMC: PMC6949113 DOI: 10.1371/journal.pone.0227104

Safety, pharmacokinetics and antiviral activity of AT-527, a novel purine nucleotide prodrug, in HCV-infected subjects with and without cirrhosis.

Antimicrobial agents and chemotherapy • Vol. 63, Issue 12 • 2019

PMID: 31570394 PMC: PMC6879261 DOI: 10.1128/AAC.01201-19

Documentation

Similar Products

9-[(4aR,6R,7R,7aR)-7-fluoro-7-methyl-2-oxo-2-propan-2-yloxy-4,4a,6,7a-tetrahydrofuro[3,2-d][1,3,2]dioxaphosphinin-6-yl]-6-ethoxypurin-2-amine
CAS No.1231747-17-3
N-(9-((2R,3R,4R,5R)-5-((bis(4-methoxyphenyl)-phenylmethoxy)methyl)-4-(2-cyanoethoxy-(di(propan-2-yl)amino)phosphanyl)oxy-3-fluorooxolan-2-yl)purin-6-yl)benzamide
CAS No.136834-22-5
(2R,3R,4R,5R)-5-(2-Amino-6-chloro-9h-purin-9-yl)-2-((4-chlorobenzoyloxy)methyl)-4-fluoro-4-methyloxolan-3-yl 4-chlorobenzoate
CAS No.1294481-82-5
Dazostinag disodium
CAS No.2553413-93-5
Bz-rA Phosphoramidite
CAS No.104992-55-4
N-[9-[(1R,5R,7R,8S)-5-[[bis(4-methoxyphenyl)-phenylmethoxy]methyl]-8-[2-cyanoethoxy-[di(propan-2-yl)amino]phosphanyl]oxy-2,6-dioxabicyclo[3.2.1]octan-7-yl]purin-6-yl]benzamide
CAS No.287737-45-5

Products
- CDMO Compounds
- API & Candidates
Services
CDMO & Manufacturing
Custom Synthesis
Process Development
Lab To Pilot
Commercialization
Generic APIs
CRO
Preclinical
Pharmacology & Efficacy
DMPK & Bioanalysis
Toxicology & Safety
Disease Models
Technologies
High-Potent
Chiral Synthesis
Cloud Synthesis
Fermentation
Flow Chemistry
Biocatalysis
Support
Regulatory Support
Supply Chain Solutions
About
Perspectives
Contact

HomeHome
ProductsProducts
Building BlocksBuilding Blocks
Heterocyclic ScaffoldsHeterocyclic Scaffolds
PurinesPurines
BemnifosbuvirBemnifosbuvir

Bemnifosbuvir

CAS No.	1998705-64-8
MDL No.	N/A
MF	C₂₄H₃₃FN₇O₇P
MW	581.50
InChI Key	OISLSHLAXHALQZ-LZEIJKKFSA-N

CUSTOM SYNTHESIS

Pricing & Availability

Pack Size	Purity	Price	Availability	Action
-	-	On Request	On Request
Custom synthesis and bulk supply options are available upon request.

Product Information

CAS No.	1998705-64-8
Product Name	Bemnifosbuvir

Heavy Atom Count	40	Rotatable Bond Count	11
Atom Stereo Count	6	Bond Stereo Count	0
HBA	13	HBD	4
TPSA	184.970 Å²	Charge	0
Exact Mass	581.21631	Complexity	1390.66
pKa	7.130	XLogP	2.570

Studies related to this compound and its mechanism of action

AT-527, a Double Prodrug of a Guanosine Nucleotide Analog, Is a Potent Inhibitor of SARS-CoV-2 and a Promising Oral Antiviral for Treatment of COVID-19.

Antimicrobial agents and chemotherapy • Vol. 65, Issue 4 • 2021

PMID: 33558299 PMC: PMC8097421 DOI: 10.1128/AAC.02479-20

Preclinical evaluation of AT-527, a novel guanosine nucleotide prodrug with potent, pan-genotypic activity against hepatitis C virus.

PloS one • Vol. 15, Issue 1 • 2020

PMID: 31914458 PMC: PMC6949113 DOI: 10.1371/journal.pone.0227104

Safety, pharmacokinetics and antiviral activity of AT-527, a novel purine nucleotide prodrug, in HCV-infected subjects with and without cirrhosis.

Antimicrobial agents and chemotherapy • Vol. 63, Issue 12 • 2019

PMID: 31570394 PMC: PMC6879261 DOI: 10.1128/AAC.01201-19

Documentation

Similar Products

9-[(4aR,6R,7R,7aR)-7-fluoro-7-methyl-2-oxo-2-propan-2-yloxy-4,4a,6,7a-tetrahydrofuro[3,2-d][1,3,2]dioxaphosphinin-6-yl]-6-ethoxypurin-2-amine
CAS No.1231747-17-3
N-(9-((2R,3R,4R,5R)-5-((bis(4-methoxyphenyl)-phenylmethoxy)methyl)-4-(2-cyanoethoxy-(di(propan-2-yl)amino)phosphanyl)oxy-3-fluorooxolan-2-yl)purin-6-yl)benzamide
CAS No.136834-22-5
(2R,3R,4R,5R)-5-(2-Amino-6-chloro-9h-purin-9-yl)-2-((4-chlorobenzoyloxy)methyl)-4-fluoro-4-methyloxolan-3-yl 4-chlorobenzoate
CAS No.1294481-82-5
Dazostinag disodium
CAS No.2553413-93-5
Bz-rA Phosphoramidite
CAS No.104992-55-4
N-[9-[(1R,5R,7R,8S)-5-[[bis(4-methoxyphenyl)-phenylmethoxy]methyl]-8-[2-cyanoethoxy-[di(propan-2-yl)amino]phosphanyl]oxy-2,6-dioxabicyclo[3.2.1]octan-7-yl]purin-6-yl]benzamide
CAS No.287737-45-5

Your Partner for
Complex Chemistry

About Us
Perspectives
Products
Contact

Preclinical Development
Technologies
Custom Synthesis

Ready to start your project?

Provide your target molecule or project specifications to align on a tailored development and scale-up pathway with our scientific team.

START A PROJECT

Westerstraat 10, 3016 DH, Rotterdam, The Netherlands

All products are supplied strictly for research and development use only and are not intended for human or veterinary administration, diagnostic use, or therapeutic use. Preclinical and related services are provided solely for research and development purposes and do not constitute clinical diagnosis, treatment, or veterinary care.

CLIENT PORTAL|TERMS AND CONDITIONS|PRIVACY POLICY|

Bemnifosbuvir

Pricing & Availability

Product Information

Properties

Documentation

Bemnifosbuvir

Pricing & Availability

Product Information

Properties

Documentation

Bemnifosbuvir

Pricing & Availability

Product Information

Properties

Related Articles

AT-527, a Double Prodrug of a Guanosine Nucleotide Analog, Is a Potent Inhibitor of SARS-CoV-2 and a Promising Oral Antiviral for Treatment of COVID-19.

Preclinical evaluation of AT-527, a novel guanosine nucleotide prodrug with potent, pan-genotypic activity against hepatitis C virus.

Safety, pharmacokinetics and antiviral activity of AT-527, a novel purine nucleotide prodrug, in HCV-infected subjects with and without cirrhosis.

Documentation

Similar Products

9-[(4aR,6R,7R,7aR)-7-fluoro-7-methyl-2-oxo-2-propan-2-yloxy-4,4a,6,7a-tetrahydrofuro[3,2-d][1,3,2]dioxaphosphinin-6-yl]-6-ethoxypurin-2-amine

N-(9-((2R,3R,4R,5R)-5-((bis(4-methoxyphenyl)-phenylmethoxy)methyl)-4-(2-cyanoethoxy-(di(propan-2-yl)amino)phosphanyl)oxy-3-fluorooxolan-2-yl)purin-6-yl)benzamide

(2R,3R,4R,5R)-5-(2-Amino-6-chloro-9h-purin-9-yl)-2-((4-chlorobenzoyloxy)methyl)-4-fluoro-4-methyloxolan-3-yl 4-chlorobenzoate

Dazostinag disodium

Bz-rA Phosphoramidite

N-[9-[(1R,5R,7R,8S)-5-[[bis(4-methoxyphenyl)-phenylmethoxy]methyl]-8-[2-cyanoethoxy-[di(propan-2-yl)amino]phosphanyl]oxy-2,6-dioxabicyclo[3.2.1]octan-7-yl]purin-6-yl]benzamide

Bemnifosbuvir

Pricing & Availability

Product Information

Properties

Related Articles

AT-527, a Double Prodrug of a Guanosine Nucleotide Analog, Is a Potent Inhibitor of SARS-CoV-2 and a Promising Oral Antiviral for Treatment of COVID-19.

Preclinical evaluation of AT-527, a novel guanosine nucleotide prodrug with potent, pan-genotypic activity against hepatitis C virus.

Safety, pharmacokinetics and antiviral activity of AT-527, a novel purine nucleotide prodrug, in HCV-infected subjects with and without cirrhosis.

Documentation

Similar Products

9-[(4aR,6R,7R,7aR)-7-fluoro-7-methyl-2-oxo-2-propan-2-yloxy-4,4a,6,7a-tetrahydrofuro[3,2-d][1,3,2]dioxaphosphinin-6-yl]-6-ethoxypurin-2-amine

N-(9-((2R,3R,4R,5R)-5-((bis(4-methoxyphenyl)-phenylmethoxy)methyl)-4-(2-cyanoethoxy-(di(propan-2-yl)amino)phosphanyl)oxy-3-fluorooxolan-2-yl)purin-6-yl)benzamide

(2R,3R,4R,5R)-5-(2-Amino-6-chloro-9h-purin-9-yl)-2-((4-chlorobenzoyloxy)methyl)-4-fluoro-4-methyloxolan-3-yl 4-chlorobenzoate

Dazostinag disodium

Bz-rA Phosphoramidite

N-[9-[(1R,5R,7R,8S)-5-[[bis(4-methoxyphenyl)-phenylmethoxy]methyl]-8-[2-cyanoethoxy-[di(propan-2-yl)amino]phosphanyl]oxy-2,6-dioxabicyclo[3.2.1]octan-7-yl]purin-6-yl]benzamide